197 related articles for article (PubMed ID: 23829895)
1. Pathogen reduction treatment alters the immunomodulatory capacity of buffy coat-derived platelet concentrates.
Loh YS; Johnson L; Kwok M; Marks DC
Transfusion; 2014 Mar; 54(3):577-84. PubMed ID: 23829895
[TBL] [Abstract][Full Text] [Related]
2. Effects of a new pathogen-reduction technology (Mirasol PRT) on functional aspects of platelet concentrates.
Perez-Pujol S; Tonda R; Lozano M; Fuste B; Lopez-Vilchez I; Galan AM; Li J; Goodrich R; Escolar G
Transfusion; 2005 Jun; 45(6):911-9. PubMed ID: 15934989
[TBL] [Abstract][Full Text] [Related]
3. Pathogen reduction treatment using riboflavin and ultraviolet light impairs platelet reactivity toward specific agonists in vitro.
Zeddies S; De Cuyper IM; van der Meer PF; Daal BB; de Korte D; Gutiérrez L; Thijssen-Timmer DC
Transfusion; 2014 Sep; 54(9):2292-300. PubMed ID: 24689812
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of platelet mitochondria integrity after treatment with Mirasol pathogen reduction technology.
Li J; Lockerbie O; de Korte D; Rice J; McLean R; Goodrich RP
Transfusion; 2005 Jun; 45(6):920-6. PubMed ID: 15934990
[TBL] [Abstract][Full Text] [Related]
5. Platelet capacity of various platelet pooling systems for buffy coat-derived platelet concentrates.
Dijkstra-Tiekstra MJ; Kuipers W; Setroikromo AC; de Wildt-Eggen J
Transfusion; 2008 Oct; 48(10):2114-21. PubMed ID: 18647365
[TBL] [Abstract][Full Text] [Related]
6. Cell integrity and mitochondrial function after Mirasol-PRT treatment for pathogen reduction of apheresis-derived platelets: Results of a three-arm in vitro study.
Picker SM; Steisel A; Gathof BS
Transfus Apher Sci; 2009 Apr; 40(2):79-85. PubMed ID: 19233725
[TBL] [Abstract][Full Text] [Related]
7. Platelet products prepared by different methods of sedimentation undergo platelet activation differently during storage.
Skripchenko A; Kurtz J; Moroff G; Wagner SJ
Transfusion; 2008 Jul; 48(7):1469-77. PubMed ID: 18482181
[TBL] [Abstract][Full Text] [Related]
8. Pathogen reduction treatment of buffy coat platelet concentrates in additive solution induces proapoptotic signaling.
Reid S; Johnson L; Woodland N; Marks DC
Transfusion; 2012 Oct; 52(10):2094-103. PubMed ID: 22320126
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of platelet activation and cytokine release during storage of platelet concentrates processed from buffy coats either manually or by the automated OrbiSac system.
Vetlesen A; Mirlashari MR; Ezligini F; Kjeldsen-Kragh J
Transfusion; 2007 Jan; 47(1):126-32. PubMed ID: 17207241
[TBL] [Abstract][Full Text] [Related]
10. Lack of antibody formation to platelet neoantigens after transfusion of riboflavin and ultraviolet light-treated platelet concentrates.
Ambruso DR; Thurman G; Marschner S; Goodrich RP
Transfusion; 2009 Dec; 49(12):2631-6. PubMed ID: 19694996
[TBL] [Abstract][Full Text] [Related]
11. Flow cytometric assessment of agonist-induced P-selectin expression as a measure of platelet quality in stored platelet concentrates.
Middelburg RA; Roest M; Ham J; Coccoris M; Zwaginga JJ; van der Meer PF
Transfusion; 2013 Aug; 53(8):1780-7. PubMed ID: 23216254
[TBL] [Abstract][Full Text] [Related]
12. Donor platelets stored for at least 3 days can elicit activation marker expression by the recipient's blood mononuclear cells: an in vitro study.
Cognasse F; Hamzeh-Cognasse H; Lafarge S; Acquart S; Chavarin P; Courbil R; Fabrigli P; Garraud O
Transfusion; 2009 Jan; 49(1):91-8. PubMed ID: 18954408
[TBL] [Abstract][Full Text] [Related]
13. Effects of Mirasol PRT treatment on storage lesion development in plasma-stored apheresis-derived platelets compared to untreated and irradiated units.
Picker SM; Steisel A; Gathof BS
Transfusion; 2008 Aug; 48(8):1685-92. PubMed ID: 18513255
[TBL] [Abstract][Full Text] [Related]
14. Platelet function assessed by shear-induced deposition of split triple-dose apheresis concentrates treated with pathogen reduction technologies.
Picker SM; Schneider V; Gathof BS
Transfusion; 2009 Jun; 49(6):1224-32. PubMed ID: 19220821
[TBL] [Abstract][Full Text] [Related]
15. Real-time measurement of platelet shape change by light scattering under riboflavin and ultraviolet light treatment.
Terada C; Shiba M; Satake M; Tadokoro K
Transfusion; 2016 Mar; 56(3):587-95. PubMed ID: 26536611
[TBL] [Abstract][Full Text] [Related]
16. Riboflavin and UV light treatment of platelets: a protective effect of platelet additive solution?
van der Meer PF; Bontekoe IJ; Daal BB; de Korte D
Transfusion; 2015 Aug; 55(8):1900-8. PubMed ID: 25752624
[TBL] [Abstract][Full Text] [Related]
17. Preserved functional and biochemical characteristics of platelet components prepared with amotosalen and ultraviolet A for pathogen inactivation.
Hechler B; Ohlmann P; Chafey P; Ravanat C; Eckly A; Maurer E; Mangin P; Isola H; Cazenave JP; Gachet C
Transfusion; 2013 Jun; 53(6):1187-200. PubMed ID: 23067365
[TBL] [Abstract][Full Text] [Related]
18. Proteomic analysis of supernatant from pooled buffy-coat platelet concentrates throughout 7-day storage.
Glenister KM; Payne KA; Sparrow RL
Transfusion; 2008 Jan; 48(1):99-107. PubMed ID: 17894789
[TBL] [Abstract][Full Text] [Related]
19. Riboflavin and ultraviolet light treatment potentiates vasodilator-stimulated phosphoprotein Ser-239 phosphorylation in platelet concentrates during storage.
Schubert P; Culibrk B; Coupland D; Scammell K; Gyongyossy-Issa M; Devine DV
Transfusion; 2012 Feb; 52(2):397-408. PubMed ID: 21827504
[TBL] [Abstract][Full Text] [Related]
20. Pathogen reduction of buffy coat platelet concentrates using riboflavin and light: comparisons with pathogen-reduction technology-treated apheresis platelet products.
Li J; de Korte D; Woolum MD; Ruane PH; Keil SD; Lockerbie O; McLean R; Goodrich RP
Vox Sang; 2004 Aug; 87(2):82-90. PubMed ID: 15355498
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
